Achievements from our 2013–2018 research strategy
In 2013 we published our first official research strategy on how we wanted to fund research towards beating cystic fibrosis (CF) for good. Below we look back on how we did.
Our aim was to fund research to enable people with CF to live longer, healthier lives, unlimited by the condition.
To achieve this, we have invested in research to alleviate and manage the symptoms and consequences of living with CF (‘research for today’) and to understand the CFTR gene defect and how to correct it (‘research for tomorrow’).
-
What we said we’d do
We said we’d fund research in a number of different ways:
Strategic Research Centres
You asked us to think big and harness global research expertise, rather than focusing on just the UK. In response, we developed the SRC programme to bring together researchers working around the world to collaborate to solve the issues that matter to people with cystic fibrosis.
Venture and Innovation Awards
We committed to bringing external funds into CF research by funding studies that turn research results in the lab into effective treatments in the clinic by bringing in additional external funds to achieve this.
Research sandpits
We agreed to address research areas that are of importance to people with CF but are not well understood.
In all three programmes we also said we would:
- Increase the capacity and quality of clinical research in the UK
- Attract the brightest and the best early career researchers to work in cystic fibrosis
- Work with the CF community to shape our research plans
Read our 2013-2018 research strategy to learn more about what we said we'd do.
-
What we’ve done
Strategic Research Centres
We funded 14 Strategic Research Centres, comprising of 96 investigators, based in over 35 institutions in 14 countries.
Find out more about the topics we funded.
“From the second year on, we began proactively to focus on synergy between projects, which has led to substantial cross-fertilisation and a genuine feeling of collaboration, rather than a number of individual, siloed projects” – Professor Jane Davies, principal investigator of SRC, Imperial College London
“The SRC provides access to additional sites, resources and expertise that I wouldn’t have been able to access on my own” – Dr Catriona Kelly, co-investigator of SRC, Ulster
The Strategic Research Centres have additionally demonstrated a number of unexpected valuable outcomes, shown below.
Venture and Innovation Awards
We funded 56 Venture and Innovation Awards with universities, government funding bodies, other research charities and pharmaceutical and biotech companies. For every £1 we’ve spent, we’ve brought in almost £4 of external money into CF research.
Find out how we work with partners on our VIA page.
GI tract research
We launched two innovative research programmes on GI tract problems in CF, as a result of our research sandpit bringing together experts from a wide range of disciplines.
Find out more about GI tract research.
Clinical Trials Accelerator Platform
We initiated our flagship Clinical Trials Accelerator Platform (CTAP) to increase the capacity and quality of clinical research.
Find out more about the Trials Accelerator.
Early career researchers
Attracted over 40 early career researchers to work in the field of CF research, as part of our Strategic Research Centres.
“The funding provided for PhD students is an excellent way to introduce new investigators into CF research. The collaborative network has been critical to providing additional support to students, which has resulted in better projects that are more thoroughly conducted and results are better interpreted” Dr Sanja Stanojevic, co-investigator of SRC, Hospital for Sick Children, Canada
Strategy Implementation Board
We formed our Strategy Implementation Board including people from the community living with or affected by cystic fibrosis.
"The transparent environment of discussion and ideas in SIB meetings opens up vital lines of communication to enable the Trust to focus on the issues that matter deeply to us. I do think it's vital to include patient and parent input in the decisions that will shape our future, and it's extremely exciting to be a part of" Laura Taylor, member of SIB who has cystic fibrosis.
Read more about the achievements of our 2013–2018 research strategy in detail.
-
What's next?
Our 2018–2023 research strategy is called ‘putting the person into personalised medicine’. It sets out how our research investments will focus on research to deliver treatment and care that is tailored to each individual with cystic fibrosis.
Research we fund
We fund research to tackle some of the most pressing issues in CF today. Find out how your donations are making a difference.
What is CF?
Cystic fibrosis, or CF, affects the lungs, digestive system and other organs. There are around 11,000 people living with it in the UK.
Contact us
Get in touch with us to speak to someone on our Helpline, find out about an event or speak to our press team.